Genentech, a member of the Roche Group, confirmed that following the reviews of AvastinĀ® (bevacizumab) in metastatic breast cancer by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), the following regulatory announcements were made by the individual health authorities:
More...